I compiled a summary of US sales for DAYBUE and SKYCLARYS, same launch time, DAYBUE has been performing better than SKYCLARYS in sales in US.
Given SKYCLARYS/Reata was acquired in 2023 for US$7.3B, NEU is still valued at US$1.05B with net cash around $320m including US$50m milestone payment to receive this quarter less accrued income tax.
According to Acadia sale guidance, NEU will receive royalties for 2025 DAYBUE sales, royalties will be around $64m to $69m, then likely another milestone payment for first Europe sale of US$35m/$55m, and bank interest income around $16m, NEU 2025 income are likely to be around $135m to $140m, on top of existing net cash position of around $320m, based on my estimates.
DYOR & ALL IMO.
![]()
- Forums
- ASX - By Stock
- NEU
- Acadia
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.48%
!
$12.48

Acadia, page-1357
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.48 |
Change
-0.060(0.48%) |
Mkt cap ! $1.548B |
Open | High | Low | Value | Volume |
$12.61 | $12.68 | $12.32 | $4.527M | 362.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
25 | 916 | $12.47 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.49 | 1575 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
22 | 797 | 12.470 |
4 | 765 | 12.460 |
4 | 810 | 12.450 |
4 | 1481 | 12.440 |
6 | 2189 | 12.430 |
Price($) | Vol. | No. |
---|---|---|
12.490 | 1489 | 8 |
12.500 | 5298 | 11 |
12.510 | 4203 | 11 |
12.520 | 2458 | 11 |
12.530 | 1924 | 6 |
Last trade - 14.31pm 25/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |